Abstract:BACKGROUND: Emerging evidence suggests that long noncoding RNAs (lncRNAs) play crucial roles in various cancers. In the present study, we aim to investigate the function and molecular mechanism of an up-regulated and survival-associated lncRNA, LINC00525, in lung adenocarcinoma (LUAD).METHODS: The expression level of LINC00525 in tissues was determined by quantitative reverse transcription polymerase chain reaction (RT-qPCR) and in situ hybridization (ISH). The functional role of LINC00525 in LUAD was investigated using gain-and loss-of-function approaches, both in vivo and in vitro. RNA pull-down, RNA immunoprecipitation (RIP), chromatin immunoprecipitation (ChIP), triplex-capture assay, dual-luciferase assay, gene expression microarray, and bioinformatics analysis were used to investigate the potential underlying mechanisms involved.RESULTS: LINC00525 is highly expressed in LUAD cells and tissues. Survival analysis indicated that upregulation of LINC00525 was associated with poor prognosis in patients with LUAD patients. Knockdown of LINC00525 inhibited cell proliferation and cell cycle progression in vitro. In xenograft models, LINC00525 knockdown suppressed tumor growth and tumorigenesis of tumor-bearing mice. Mechanistically, LINC00525 epigenetically suppressed p21 transcription by guiding Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit (EZH2) to the p21 promoter through an formation of RNA-DNA triplex with the p21 promoter, leading to increased trimethylation of lysine 27 on histone 3 (H3K27me3) of the p21 promoter. In addition, LINC00525 repressed p21 expression post-transcriptionally by enhancing p21 mRNA decay. LINC00525 promoted p21 mRNA decay by competitively binding to RNA Binding Motif Single Stranded Interacting Protein 2 (RBMS2).CONCLUSION: Our findings demonstrate that LINC00525 promotes the progression of LUAD by reducing the transcription and stability of p21 mRNA in concert with EZH2 and RBMS2, thus suggesting that LINC00525 may be a potential therapeutic target for clinical intervention in LUAD.

LINC00908 promotes malignant progression and glycolysis in lung adenocarcinoma via interactions with DDX54 and RFX2

Linc00901 Regulates Glucose Metabolism In Pancreatic Cancer.

Abstract 2389: LINC00901 Regulates Glucose Metabolism in Pancreatic Cancer

LINC00665 promotes glycolysis in lung adenocarcinoma cells via the let-7c-5p/HMMR axis

LINC00941 is a diagnostic biomarker for lung adenocarcinoma and promotes tumorigenesis through cell autophagy

Non-coding RNA LINC00857 is predictive of poor patient survival and promotes tumor progression via cell cycle regulation in lung cancer

The super-enhancer-driven lncRNA LINC00880 acts as a scaffold between CDK1 and PRDX1 to sustain the malignance of lung adenocarcinoma

Low expression of LINC00982 and PRDM16 is associated with altered gene expression, damaged pathways and poor survival in lung adenocarcinoma.

Bioinformatics and Experimental Study Revealed LINC00982/ miR-183-5p/ABCA8 Axis Suppresses LUAD Progression

LINC00842 inactivates transcription co-regulator PGC-1α to promote pancreatic cancer malignancy through metabolic remodelling

Linc00426 Accelerates Lung Adenocarcinoma Progression by Regulating Mir-455-5p As a Molecular Sponge

Long Non-Coding RNA DUXAP8 Facilitates Cell Viability, Migration, and Glycolysis in Non-Small-Cell Lung Cancer Via Regulating HK2 and LDHA by Inhibition of Mir-409-3p

LINC00891 Regulated by Mir-128-3p/gata2 Axis Impedes Lung Cancer Cell Proliferation, Invasion and EMT by Inhibiting RhoA Pathway.

Long non-coding RNA LINC01116 is overexpressed in lung adenocarcinoma and promotes tumor proliferation and metastasis

LncRNA LINC00520 Aggravates Cell Proliferation and Migration in Lung Adenocarcinoma Via a Positive Feedback Loop

LncRNA LINC00525 suppresses p21 expression via mRNA decay and triplex‐mediated changes in chromatin structure in lung adenocarcinoma

LINC00152 induced by TGF-beta promotes metastasis via HuR in lung adenocarcinoma

Linc00152 Promotes Cancer Cell Proliferation and Invasion and Predicts Poor Prognosis in Lung Adenocarcinoma

Abnormal methylation mediated upregulation of LINC00857 boosts malignant progression of lung adenocarcinoma by modulating the miR‐486‐5p/NEK2 axis

LINC00152 induced by TGF-β promotes metastasis via HuR in lung adenocarcinoma